Breaking Down AbbVie: 7 Analysts Share Their Views

AbbVie ABBV underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $171.57, a high estimate of $196.00, and a low estimate of $150.00. Observing a downward trend, the current average is 1.06% lower than the prior average price target of $173.40.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of AbbVie by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AbbVie. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AbbVie's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on AbbVie analyst ratings.

Get to Know AbbVie Better

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Breaking Down AbbVie's Financial Performance

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.

Decline in Revenue: Over the 3 months period, AbbVie faced challenges, resulting in a decline of approximately -5.97% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: AbbVie's net margin excels beyond industry benchmarks, reaching 12.77%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): AbbVie's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 14.25%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): AbbVie's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.31% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: AbbVie's debt-to-equity ratio surpasses industry norms, standing at 5.02. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.